Clinical Trials Browser

NCT07262970 2025-12-04

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Clinical Trials

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Expanded Access Program of Surufatinib

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Expanded Access Protocol Using 131I-MIBG

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial